Blueprint Medicines (FRA:2L9) 3-Year Book Growth Rate : -56.20% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines 3-Year Book Growth Rate?

Blueprint Medicines's Book Value per Share for the quarter that ended in Mar. 2024 was €4.57.

During the past 12 months, Blueprint Medicines's average Book Value per Share Growth Rate was -27.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was -56.20% per year. During the past 5 years, the average Book Value per Share Growth Rate was -20.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Blueprint Medicines was 21.40% per year. The lowest was -56.20% per year. And the median was 16.75% per year.

Competitive Comparison of Blueprint Medicines's 3-Year Book Growth Rate

For the Biotechnology subindustry, Blueprint Medicines's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blueprint Medicines's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's 3-Year Book Growth Rate falls into.

Blueprint Medicines 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Blueprint Medicines (FRA:2L9) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Blueprint Medicines 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (FRA:2L9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

BPMC:USA 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (FRA:2L9) Headlines

No Headlines